- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Hodgkin's Lymphoma - September 2002
National Cancer Institute®
Last Modified: September 1, 2002
- [Giant cell lymphosarcoma or lymphogranulomatosis variants?]
- CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD.
- Eosinophilic folliculitis occurring in a patient affected by Hodgkin lymphoma.
- Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.
- Long-term survival of a patient with human immunodeficiency virus infection and Hodgkin's lymphoma.
- Challenging cases and diagnostic dilemmas: case 1. Tracheal compression in Hodgkin's disease.
- PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
- Trends in mortality from Hodgkin's disease in western and eastern Europe.
- Role of radiation therapy in advanced Hodgkin's disease--as yet, an answer? Still a question?
- Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy
- Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete
- Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma
- Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease.
- Hodgkin's disease following methotrexate therapy for rheumatoid arthritis.
- Primary mediastinal large B-cell lymphoma: a comparative study with nodular sclerosis-type Hodgkin's disease.
- Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma.
- Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era.
- From chronic lymphocytic leukemia to Hodgkin's disease: a case of prognostically favorable transformation.
- Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after
- Paraneoplastic cerebellar degeneration and nephrotic syndrome preceding Hodgkin's disease: case report and review of the literature.
- EMMPRIN (CD 174) is expressed in Hodgkin's lymphoma and anaplastic large cell lymphoma. An immunohistochemical study of 60 cases.
- Lung function and serum concentrations of different cytokines in patients submitted to radiotherapy and intermediate/high dose
- Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a
- Ofuji papuloerythroderma associated with Hodgkin's lymphoma.
- Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.
- LMP1-induced downregulation of CD99 molecules in Hodgkin and Reed-Sternberg cells.
- Is it wise to eliminate lymphography from the staging of Hodgkin's disease?
- Hodgkin's disease: unsuspected minimal activity in patients that die from causes other than tumoral progression.
- Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A & B Hodgkin's disease.
- Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB.
- Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.
- Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells.
- Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.
- Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.
- Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
- Value of fine needle aspiration cytology in the initial diagnosis of Hodgkin's disease. Analysis of 188 cases with an emphasis on diagnostic
- Fine needle aspiration in Hodgkin's disease.
- Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease.
- Multiple cavitating pulmonary nodules and clubbing in a 12-year-old girl.
- Sternal osteomyelitis caused by Aspergillus fumigatus in a patient with previously treated Hodgkin's disease.
- Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease.
- Interventions for early stage Hodgkin's disease in children.
- Interventions for early stage Hodgkin's disease in children.
- Miller-Fisher syndrome and Hodgkin's disease.
- CD44 variant exons in leukemia and lymphoma.
- Utility and outcomes of fine-needle aspiration biopsy in Hodgkin's disease.
- Pediatric Hodgkin's disease--up, up, and beyond.
- Viruses and Hodgkin disease: no evidence of novel herpesviruses in non-EBV-associated lesions.
- T-cell variant of classical Hodgkin's lymphoma with nodal and cutaneous manifestations demonstrated by single-cell polymerase chain reaction.
- [Acquired ichthyosis disclosing Hodgkin's disease. Simultaneous recurrence]
- Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas.
- Expression of gene MAGE-A4 in Reed-Sternberg cells.
- Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including
- In regard to Gaffney et al., IJROBP 2001;49:539-546.
- [Tumor of the nasopharyngeal wall. Hodgkin lymphoma (Hodgkin disease), nodular sclerosis, grade 1, stage Ia, primary manifestation of the
- High-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's lymphoma: a single center experience.
- Radiotherapy for early stage of Hodgkin's disease at Kuwait Cancer Control Center, Kuwait.
Table of Contents
1
UI - 12181835
AU - Kremenetskaia AM; Vorob'ev AI; Kharazishvili DV; Frank GA; Vorob'ev IA;
TI -
Kaplanskaia IB; Kravchenko SK; Moiseeva TN; Shklovskii-Kordi NE;
Chernova NG; Lorie IuIu
[Giant cell lymphosarcoma or lymphogranulomatosis variants?]
SO - Ter Arkh 2002;74(7):48-52
2
UI - 12171718
AU - Blystad AK; Torlakovic E; Holte H; Kvaloy S; Lenschow E; Kvalheim G
TI -
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts
in patients with HD.
SO - Cytotherapy 2001;3(4):295-305
AD - Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway.
BACKGROUND: European Group for Blood and Marrow Transplantation (EBMT)
registry data indicate that patients with relapsed HD given high-dose
therapy (HDT), supported with PBPC might have a poorer outcome compared
with those given BM. Since this can be due to the infusion of
contaminating tumor cells in the PBPC products, we studied the presence
of minimal residual disease and tested whether CD34(+) cell enrichment
was able to remove atypical CD30(+) cells from PBPC grafts. METHODS:
Eighteen HD patients eligible for HDT were included in the study. By the
use of immunocytochemistry (ICC), mononuclear cells from BM and
peripheral blood (PB) before mobilization, PBPC products and selected
CD34(+) fractions were stained using anti-CD30 MAb (Ber-H2) and the
APAAP (alkaline phosphatase-anti-alkaline phosphatase) method. Cells
scored as atypical CD30(+) cells were large- to medium-sized, with
membranous, cytoplasmatic and/or Golgi positivity for CD30. RESULTS:
Nine out of 11 BM tested were positive, while 14 of 14 PB and 18 of 18
PBPC contained atypical CD30(+) cells. The total number of atypical
CD30(+) cells was significantly higher in PBPC than in the corresponding
BM. CD34(+) cell enrichment employing ISOLEX 300I gave a purity and
yield of 99.2% (range 97.8-99.7) and 49.6% (range 30.0-78.4),
respectively. After HDT a median of 5.8 x 10(6) (range 2.7-20) CD34(+)
cells/kg was infused. Neutrophil counts of > 0.5 x 10(9)/L and platelet
counts of > 20 x 10(9)/L were achieved at Day 12 (range 10-17) and at
Day 10 (range 7-15), respectively. Sixteen of 18 CD34(+) selected
products had no detectable atypical CD30(+) cells, while two had a low
number. After HDT, the overall survival was 80% and the event-free
survival was 69%, with a median follow-up of 24 months (range 1-36).
DISCUSSION: We show that contaminating atypical CD30(+) cells in PBPC
can efficiently be removed by CD34(+) cell enrichment, and the use of
such grafts following HDT gives fast and sustained engraftment.
3
UI - 12100711
AU - Vassallo C; Ciocca O; Arcaini L; Brazzelli V; Ardigo M; Lazzarino M;
TI -
Borroni G
Eosinophilic folliculitis occurring in a patient affected by Hodgkin
lymphoma.
SO - Int J Dermatol 2002 May;41(5):298-300
AD - Department of Dermatology, and the Institute of Hematology, University
of Pavia, Policlinico S. Matteo-IRCCS, Italy. cvassallo@yahoo.com
4
UI - 12177110
AU - Dores GM; Metayer C; Curtis RE; Lynch CF; Clarke EA; Glimelius B; Storm
TI -
H; Pukkala E; van Leeuwen FE; Holowaty EJ; Andersson M; Wiklund T;
Joensuu T; van't Veer MB; Stovall M; Gospodarowicz M; Travis LB
Second malignant neoplasms among long-term survivors of Hodgkin's
disease: a population-based evaluation over 25 years.
SO - J Clin Oncol 2002 Aug 15;20(16):3484-94
AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Executive Plaza South, Suite 7039, Bethesda, MD 20892, USA.
doresg@mail.nih.gov
PURPOSE: To quantify the relative and absolute excess risks (AER) of
site-specific second cancers, in particular solid tumors, among
long-term survivors of Hodgkin's disease (HD) and to assess risks
according to age at HD diagnosis, attained age, and time since initial
treatment. PATIENTS AND METHODS: Data from 32,591 HD patients (1,111
25-year survivors) reported to 16 population-based cancer registries in
North America and Europe (1935 to 1994) were analyzed. RESULTS: Two
thousand one hundred fifty-three second cancers (observed-to-expected
ratio [O/E] = 2.3; 95% confidence interval [CI] = 2.2 to 2.4), including
1,726 solid tumors (O/E = 2.0; 95% CI, 1.9 to 2.0) were reported.
Cancers of the lung (observed [Obs] = 377; O/E = 2.9), digestive tract
(Obs = 376; O/E = 1.7), and female breast (Obs = 234; O/E = 2.0)
accounted for the largest number of subsequent malignancies. Twenty-five
years after HD diagnosis, the actuarial risk of developing a solid tumor
was 21.9%. The relative risk of solid neoplasms decreased with
increasing age at HD diagnosis, however, patients aged 51 to 60 years at
HD diagnosis sustained the highest cancer burden (AER = 79.2/10,000
patients/year). After a progressive rise in relative risk and AER of all
solid tumors over time, there was an apparent downturn in risk at 25
years. Temporal trends and treatment group distribution for cancers of
the esophagus, stomach, rectum, female breast, bladder, thyroid, and
bone/connective tissue were suggestive of a radiogenic effect.
CONCLUSION: Significantly increased risks of second cancers were
observed in all HD age groups. Although significantly elevated risks of
stomach, female breast, and uterine cervix cancers persisted for 25
years, an apparent decrease in relative risk and AER of solid tumors at
other sites is suggested.
5
UI - 12190241
AU - Diwan AH; Umbreit J; Nelson BP
TI -
Long-term survival of a patient with human immunodeficiency virus
infection and Hodgkin's lymphoma.
SO - South Med J 2002 Aug;95(8):943-4
AD - Department of Pathology, University of South Alabama, Mobile, USA.
When patients infected with human immunodeficiency virus (HIV) are found
to have Hodgkin's lymphoma (HL), it is generally advanced, with
involvement of extranodal sites including bone marrow, spleen, and
liver, and prognosis tends to be unfavorable. We present the case of a
38-year-old white man who had HIV and HL diagnosed in 1990. Despite
presenting with stage IV HL, having recurrence of HL after initially
attaining remission, and being hospitalized on several occasions for
opportunistic infections, he ultimately achieved complete remission of
HL and is alive 9 years after initial diagnosis. This case illustrates
that although unusual, prolonged survival of an HIV-infected patient
with HL associated with poor prognostic features is possible.
6
UI - 12149308
AU - Garrison MA; Glanton C; Rasnke M; Smith ME; Ornstein DL
TI -
Challenging cases and diagnostic dilemmas: case 1. Tracheal compression
in Hodgkin's disease.
SO - J Clin Oncol 2002 Aug 1;20(15):3344-7
AD - Brooke Army Medical Center and Wilford Hall Medical Center, San Antonio,
TX, USA.
7
UI - 12163626
AU - Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
TI -
PET predicts prognosis after 1 cycle of chemotherapy in aggressive
lymphoma and Hodgkin's disease.
SO - J Nucl Med 2002 Aug;43(8):1018-27
AD - Division of Nuclear Medicine, Department of Radiology, Weill Medical
College of Cornell University and New York Presbyterian Hospital, New
York, New York 10021, USA. lak2005@mail.med.cornell.edu
Early identification of chemotherapy-refractory lymphoma patients
provides a basis for alternative treatment strategies. Metabolic imaging
with (18)F-FDG PET offers functional tissue characterization that is
useful for assessing response to therapy. Our objective was to determine
the predictive value of (18)F-FDG PET early during chemotherapy (after 1
cycle) and at the completion of chemotherapy for subsequent
progression-free survival (PFS) in patients with aggressive
non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). METHODS:
(18)F-FDG PET (dual-head coincidence camera with attenuation correction)
was performed before and after 1 cycle of chemotherapy on 30 patients
(17 NHL, 13 HD; mean age, 52.3 +/- 16.0 y). For 23 of the 30 patients,
(18)F-FDG PET data were also obtained after the completion of
chemotherapy. The patients had a median follow-up of 19 mo (range, 18-24
mo). Follow-up of PFS was compared between patients with positive and
negative (18)F-FDG PET results obtained after the first cycle of
chemotherapy and at the completion of chemotherapy. RESULTS: Positive
(18)F-FDG PET results obtained both after the first cycle and at the
completion of therapy were associated with a shorter PFS (median, 5 and
0 mo, respectively) than were negative (18)F-FDG PET results (PFS
medians not reached). A statistically significant difference in PFS
between positive and negative (18)F-FDG PET results was obtained both
after the first cycle and at the completion of chemotherapy (P < or =
0.001). The PFS and (18)F-FDG PET results obtained after the first cycle
correlated better than those obtained after the completion of
chemotherapy (r(2) = 0.45 vs. 0.17). (18)F-FDG PET had more
false-negative results after the last cycle (6/17 cases, or 35%) than
after the first cycle (2/13 cases, or 15%). Thus, (18)F-FDG PET had
greater sensitivity and positive predictive values after the first cycle
(82% vs. 45.5% and 90% vs. 83%, respectively) than after the last cycle.
CONCLUSION: (18)F-FDG PET after 1 cycle of chemotherapy is predictive of
18-mo outcome in patients with aggressive NHL and HD and may earlier
identify patients who would benefit from more intensive treatment
programs.
8
UI - 12177797
AU - Levi F; Lucchini F; Negri E; Boyle P; La Vecchia C
TI -
Trends in mortality from Hodgkin's disease in western and eastern
Europe.
SO - Br J Cancer 2002 Jul 29;87(3):291-3
AD - Cancer Epidemiology Unit and Cancer Registries of Vaud and Neuchatel,
Institut universitaire de medecine sociale et preventive, CHUV-Falaises
1, 1011 Lausanne, Switzerland. Fabio.Levi@inst.hospvd.ch
Hodgkin's disease mortality rates steadily declined by about 75% between
the late 1960's and the late 1990's in the current European Union
countries and the USA, and Japan. Eastern European countries, however,
showed only an approximately 40% decline between the late 1960's and the
early 1990's, and no further fall thereafter. Copyright 2002 Cancer
Research UK
9
UI - 1498069
AU - Sutcliffe SB
TI -
Role of radiation therapy in advanced Hodgkin's disease--as yet, an
answer? Still a question?
SO - Ann Oncol 1992 Jul;3(7):499-501
10
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
UI - 12100147
AU - Delwail V; Jais JP; Colonna P; Andrieu JM
TI -
Fifteen-year secondary leukaemia risk observed in 761 patients with
Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy
plus high-dose irradiation.
SO - Br J Haematol 2002 Jul;118(1):189-94
AD - Department of Hematology, Hopital J.Bernard, Poitiers, France.
Between 1972 and 1988, 869 adult patients received MOPP
(mechlorethamine, vincristine, procarbazine and prednisone; 462
patients) or ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine;
373 patients) and subsequent high-dose irradiation for Hodgkin's
disease. Nine patients developed a leukaemia after MOPP and four after
ABVD; 11 patients were diagnosed as acute non-lymphoblastic leukaemia
(ANLL) and two as acute lymphoblastic leukaemia (ALL). Both cases of ALL
were observed after ABVD and were associated with a 11q23 translocation.
The 15-year actuarial risk of secondary leukaemia was 2.4% for the whole
group of patients, 3.4% after MOPP and 1.3% after ABVD. For the MOPP
subgroup, the risk of leukaemia was significantly associated with the
extent of irradiation: 2.4% for limited irradiation and 13.9% for
extended irradiation (P < 0.001). For the ABVD subgroup, this risk
remained low (1.3%) whatever the type of irradiation. Concerning ANLL,
the MOPP regimen was significantly associated with a higher risk: 3.4%
versus 0.7% for ABVD (P
UI - 12100148
AU - Reynolds GM; Billingham LJ; Gray LJ; Flavell JR; Najafipour S; Crocker
TI -
J; Nelson P; Young LS; Murray PG
Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated
with the presence of 'B' symptoms and failure to achieve complete
remission in patients with advanced Hodgkin's disease.
SO - Br J Haematol 2002 Jul;118(1):195-201
AD - The Liver Research Laboratories, CRC Institute for Cancer Studies,
Department of Pathology, University of Birmingham, Edgbaston, UK.
Interleukin 6 (IL-6) is a potent immunomodulatory cytokine that has
pathogenic and prognostic significance in a number of disorders.
Previous studies in Hodgkin's disease (HD) have demonstrated the
association between elevated serum levels of IL-6 and unfavourable
prognosis, including advanced stage and the presence of 'B' symptoms and
with reduced survival. Although IL-6 expression has been demonstrated in
both the malignant Hodgkin/Reed-Sternberg (HRS) cells and in the various
non-malignant cells present in HD biopsies, a relationship between
expression of IL-6 by the tumour and outcome measures has not been
established. The study group comprised of 97 patients with advanced HD
who were recruited to two related clinical trials. IL-6 expression was
determined on paraffin-wax sections of biopsy material by means of an
immunohistochemical assay. Of the 97 patients, 27 (28%) showed staining
for IL-6 in HRS cells. IL-6 expression by HRS cells was significantly
correlated with a decreased likelihood of achieving a complete response
to chemotherapy (P = 0.02) and with an increased prevalence of 'B'
symptoms (P = 0.04). IL-6 expression by HRS cells was not associated
with Epstein-Barr virus status (P = 0.57). In summary, the results
suggest that IL-6 expression by HRS cells may contribute to the presence
of 'B' symptoms and to a decreased likelihood to achieve a complete
remission in HD patients.
UI - 12100149
AU - Kosmaczewska A; Frydecka I; Bocko D; Ciszak L; Teodorowska R
TI -
Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's
disease with proliferative activity, interleukin 2 and interferon-gamma
production.
SO - Br J Haematol 2002 Jul;118(1):202-9
AD - Institute of Immunology and Experimental Therapy, Polish Academy of
Sciences, Wroclaw, Poland.
Expression of the downregulatory CTLA-4 molecule was determined on
unstimulated and anti-CD3 + recombinant interleukin 2 (rIL-2)-stimulated
peripheral blood T cells in Hodgkin's disease (HD) and correlated with
the T-cells' proliferative activity, IL-2 and interferon (IFN)-gamma
production. There was a negligible percentage of CTLA-4+/CD3+ cells
before culture. The mean percentage of CTLA-4+/CD3+ lymphocytes
increased gradually, peaked after 72 h of stimulation and returned to
basal values after 96 h of stimulation. The mean proportion of
CTLA-4+/CD3+ cells from untreated patients was significantly higher
after 24, 48 and 72 h of stimulation compared with controls. The mean
percentage of CTLA-4+/CD3+ cells from patients in clinical remission
(CR) was lower than that of untreated patients, but remained
significantly higher compared with controls. Lymphocytes from untreated
HD patients showed impaired proliferative activity, IL-2 and IFN-gamma
production compared with controls. The proliferative activity of the
lymphocytes, IL-2 and IFN-gamma production remained significantly lower
in CR compared with controls. The proportion of CTLA-4+/CD3+ cells
negatively correlated with proliferative activity, IL-2 and IFN-gamma
production in HD patients and controls. However, some untreated patients
as well as patients in CR with normal mean fluorescence intensity values
of CTLA-4 showed unimpaired T-cell function tests. Our study provides
the first evidence of an increased expression of downregulatory CTLA-4
molecule on stimulated T-cells in HD, which could be one of the
mechanisms of immune deficiency in this disease.
UI - 12177773
AU - Blackhall FH; Atkinson AD; Maaya MB; Ryder WD; Horne G; Brison DR;
TI -
Lieberman BA; Radford JA
Semen cryopreservation, utilisation and reproductive outcome in men
treated for Hodgkin's disease.
SO - Br J Cancer 2002 Aug 12;87(4):381-4
AD - Cancer Research UK Department of Medical Oncology, Christie Hospital NHS
Trust, Wilmslow Road, Manchester M20 4BX, UK.
Between 1978 and 1990, 122 men underwent semen analysis before starting
sterilising chemotherapy for Hodgkin's disease. Eighty-one (66%) had
semen quality within the normal range, 25 were oligospermic (<20 x 10(6)
sperm per ml) and five were azoospermic (no sperm in the ejaculate).
Semen from 115 men was cryopreserved and after a median follow-up time
of 10.1 years, 33 men have utilised stored semen (actuarial rate 27%)
and nine partners have become pregnant resulting in 11 live births and
one termination for foetal malformation. Actuarial 10 year rates of
destruction of semen before death or utilisation and death before
utilisation are 19% and 13% respectively. This retrospective cohort
study demonstrates that approximately one-quarter of men utilising
cryopreserved semen after treatment for Hodgkin's disease obtain a live
birth. The high non-utilisation rate is intriguing and warrants further
investigation.
UI - 12199007
AU - Jardine DL; Colls BM
TI -
Hodgkin's disease following methotrexate therapy for rheumatoid
arthritis.
SO - N Z Med J 2002 Jun 21;115(1156):293-4
AD - Department of General Medicine, Christchurch Hospital, Christchurch.
David.Jardine@cdhb.govt.nz
UI - 11594519
AU - Yonetani N; Kurata M; Nishikori M; Haga H; Ohmori K; Yamabe H; Uchiyama
TI -
T; Ohno H
Primary mediastinal large B-cell lymphoma: a comparative study with
nodular sclerosis-type Hodgkin's disease.
SO - Int J Hematol 2001 Aug;74(2):178-85
AD - Department of Internal Medicine, Faculty of Medicine, Kyoto University,
Japan.
The clinicopathological features of 10 patients with primary mediastinal
large B-cell lymphoma (PMLBCL) are described. The patients were aged 19
to 63 years, with a median age of 25.5 years. There were 5 men and 5
women. All patients presented with chest symptoms, and 6 presented with
superior vena cava syndrome. Nine patients had bulky mediastinal tumors.
The disease was confined within the thorax and contiguous lymph nodes,
although multiple liver tumors were observed in 1 patient. Laboratory
findings included high lactate dehydrogenase levels and elevated
C-reactive protein levels. The soluble interleukin 2-receptor level was
high in 6 patients tested. A comparative study of PMLBCL and nodular
sclerosis-type Hodgkin's disease (NS-HD) with a mediastinal mass
revealed substantial overlap in clinical features. Histopathological
examination of biopsy specimens of PMLBCL revealed clusters of CD20+
large cells; however, CD30+ Hodgkin/Reed-Sternberg-like cells were
occasionally seen, raising the potential to misdiagnose PMLBCL as NS-HD.
The patients with PMLBCL were treated with CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisolone), biweekly CHOP, or MACOP-B
(methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone,
and bleomycin) regimen, and 6 received consolidation radiotherapy to the
involved field. With the exception of 1 patient who was primarily
refractory to therapy, 9 patients (90%) achieved complete response and 7
(70%) remain in continuous remission with a mean follow-up of 24 months.
UI - 12149227
AU - van den Berg A; Maggio E; Rust R; Kooistra K; Diepstra A; Poppema S
TI -
Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma.
SO - Blood 2002 Aug 15;100(4):1425-9
AD - Department of Pathology and Laboratory Medicine, University and
University Hospital Groningen, Groningen, The Netherlands.
Large cell lymphomas and Hodgkin disease may develop during the course
of chronic lymphocytic leukemia (CLL). In some cases the transformed
cells are Epstein-Barr virus (EBV)-positive and not clonally related to
the CLL cells. In other cases the transformed cells have the same clonal
rearrangements as the CLL cells. Here we describe a composite lymphoma
in a patient with CLL that exhibits a combination of CLL/small
lymphocytic lymphoma, large cell lymphoma with anaplastic morphology,
and Hodgkin lymphoma (HL). Although the large cell lymphoma cells are
CD45R0 and TIA-1-positive, suggesting a T- or 0-cell anaplastic large
cell lymphoma (ALCL), the genetic analysis demonstrates immunoglobulin
heavy chain (IgH) gene rearrangements for both alleles, carrying the
same somatic mutations as observed in the CLL component. The
Reed-Sternberg (R-S) cells in the Hodgkin component also strongly
express TIA-1 but differ from the anaplastic large cells by the
expression of CD15 and TARC and the presence of a prominent lymphocytic
infiltrate. The ALCL and HL components both are EBV negative. Analysis
of the IgH gene rearrangements in micromanipulated R-S cells revealed
identical Ig gene rearrangements carrying the same somatic mutations as
the CLL and the large cell components. The findings indicate
transformation of the CLL cells into a large cell lymphoma with
anaplastic morphology and a Hodgkin component.
UI - 12171776
AU - Zapatero A; Lopez MA; Cerezo L; De Vidales CM; MarIn A; Perez-Torrubia A
TI -
Stage I-III Hodgkin's disease: outcome and pattern of failure following
treatment with radiation therapy and chemotherapy in a modern era.
SO - Hematol 2002 Feb;7(1):43-50
AD - Department of Radiation Oncology, Hospital Universitario de la Princesa,
Madrid, Spain. azapatero@hlpr.inscelud.es
PURPOSE: To analyse the long term outcome, pattern of failure and
treatment related complications after radiation therapy (RT) with or
without chemotherapy for stage I-III Hodgkin's disease (HD). MATERIAL
AND METHODS: Detailed records from 86 patients with stage I-III HD
treated between 1989 and 1998, were retrospectively reviewed. Seventeen
patients with favourable stage I-IIA were treated with RT alone, and the
remaining 69 patients with combined modality treatment (CMT). Patients
treated with RT received extended-field or subtotal nodal irradiation
(STNI) to a total dose of 36-54 Gy, and patients with CMT, received
involved-field irradiation to a lower doses, 26-40 Gy. The median
follow-up time was 50 months (range 16-180). RESULTS: The 10-year
overall survival (OS) for the whole group was 96% (SE 2%), 100% for
stage I, 95% for stage II and 100% for stage III patients. Of potential
prognostic factors analysed for statistical significance, only the
response to chemotherapy (p=0.0393) was found to influence significantly
OS rates. Twelve patients (13.9%) relapsed. Salvage treatment was
effective in 10 of the 12 relapsed patients. The 10-year freedom from
treatment failure (FFTF) was 79% (SE 6%). Although 8 (9.6%) of the 83
surviving patients developed late effects that could represent toxicity
from the treatment, no patient died of late complications. CONCLUSIONs:
RT alone for favourable early stage HD attains good survival rates with
a modest treatment related morbidity. For patients with unfavourable
stage II and stage III HD, CMT with limited RT provides a good to
excellent prognosis.
UI - 12191574
AU - Zinzani PL; Tani M; Stefoni V; Piccaluga PP; Baccarani M; Ascani S;
TI -
Pileri S
From chronic lymphocytic leukemia to Hodgkin's disease: a case of
prognostically favorable transformation.
SO - Leuk Res 2002 Aug;26(8):775-6
UI - 12144535
AU - Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN;
TI -
Dimopoulou MN; Boutsis DE; Anargyrou K; Kokoris SI; Giannakakis A;
Karkantaris C; Kyrtsonis MC; Tsaftaridis P; Rombos J; Variamis E;
Korkolopoulou P; Kittas C; Pangalis GA
Hodgkin's lymphoma in first relapse following chemotherapy or combined
modality therapy: analysis of outcome and prognostic factors after
conventional salvage therapy.
SO - Eur J Haematol 2002 May;68(5):289-98
AD - Hematology Section, First Department of Internal Medicine, National and
Kapodistrian University of Athens, Laikon General Hospital, 16
Sevastoupoleos Street, Athens, Greece.
OBJECTIVES: To investigate the prognosis of patients with Hodgkin's
lymphoma (HL) who relapse following a complete remission (CR) achieved
by chemotherapy with or without radiotherapy (CT+/-RT), and to identify
prognostic factors for freedom from second progression (FF2P). METHODS:
We analyzed the prognostic significance of the initial CT regimen (4 vs.
7-8 drugs), treatment-free interval (TFI), and demographic, clinical,
and laboratory factors at the time of relapse and diagnosis, in 113
patients with HL, who relapsed after a CR achieved by CT+/-RT. RESULTS:
Conventional salvage CT+/-RT was administered in 107 patients, while six
received RT only. The 5-yr FF2P was 24%, while the 10-yr survival after
relapse (O2S) was 39% and was not afffected by the initial CT regimen.
Multivariate analysis revealed that extranodal disease at relapse
(P<0.001), TFI<6 month (P<0.001), > or =5 involved sites at diagnosis
(P=0.04) and anemia at relapse (P=0.03) were independent predictors of
FF2P. 55% of patients had 0 or 1 of these adverse prognostic factors.
The 5-yr FF2P of patients with 0, 1 or 2 adverse factors was 58%, 34%
and 5% (P<0.0001). The corresponding rates for 10-yr O2S were 68%, 51%
and 25%, respectively (P=0.002). CONCLUSIONS: Our data confirmed the
significance of TFI and extranodal relapse and demonstrated a potential
role for anemia at relapse and number of involved sites at diagnosis,
for the prognosis of patients with HL relapsing after CT+/-RT. The
combination of these prognostic factors defines a sizeable subgroup of
patients with favorable outcome following conventional salvage therapy.
UI - 12144540
AU - Spyridonidis A; Fischer KG; Glocker FX; Fetscher S; Klisch J; Behringer
TI -
D
Paraneoplastic cerebellar degeneration and nephrotic syndrome preceding
Hodgkin's disease: case report and review of the literature.
SO - Eur J Haematol 2002 May;68(5):318-21
AD - Departmentof Hematology/Oncology, University Medical Center Freiburg,
Hugstetter Strasse 55, D-79106 Freiburg, Germany.
A patient presented with symptoms of cerebellar degeneration and
nephrotic syndrome. A work-up at that time failed to reveal an
underlying disease; however, 20 months later Hodgkin's disease was
diagnosed. Hodgkin's lymphadenopathy developed 2 wk after prednisone
therapy for the nephrotic syndrome had been discontinued. Systemic
polychemotherapy resulted in complete remission of both Hodgkin's
disease and nephrotic syndrome, while the neurological deficit
persisted. Patients with unexplained cerebellar degeneration and/or
nephrotic syndrome demand extensive evaluation for the presence of
Hodgkin's disease, and steroid therapy may delay diagnosis.
UI - 12174874
AU - Thorns C; Feller AC; Merz H
TI -
EMMPRIN (CD 174) is expressed in Hodgkin's lymphoma and anaplastic large
cell lymphoma. An immunohistochemical study of 60 cases.
SO - Anticancer Res 2002 Jul-Aug;22(4):1983-6
AD - Institute of Pathology, Medical University of Luebeck, Germany.
thorns@patho.mu-luebeck.de
BACKGROUND: Matrix metalloproteinases are involved in tumor invasion and
metastatic spread. Expression of metalloproteinases is induced by the
extracellular matrix metalloproteinase inducer (EMMPRIN). Their activity
can be inhibited by several tissue inhibitors of metalloproteinases
(TIMP1-to-4). Whereas TIMP-1 expression is described for high-grade
malignant lymphomas and seems to be correlated with unfavourable
prognosis, there are no data on the expression of EMMPRIN in malignant
lymphoma. MATERIALS AND METHODS: We investigated 60 cases of Hodgkin's
lymphoma and anaplastic large cell lymphoma for TIMP-1 and EMMPRIN
expression using immunohistochemistry. RESULTS: EMMPRIN was expressed in
all but four cases. EMMPRIN and TIMP-1 were co-expressed in two-thirds
of the Hodgkin's lymphomas and anaplastic large cell lymphomas.
CONCLUSION: This is the first report on the expression of EMMPRIN in
malignant lymphoma. We speculate that EMMPRIN and TIMP-1 may be
important in the pathogenesis of anaplastic large cell lymphoma and
Hodgkin's disease.
UI - 12174934
AU - Villani F; Viola G; Vismara C; Laffranchi A; Di Russo A; Viviani S;
TI -
Bonfante V
Lung function and serum concentrations of different cytokines in
patients submitted to radiotherapy and intermediate/high dose
chemotherapy for Hodgkin's disease.
SO - Anticancer Res 2002 Jul-Aug;22(4):2403-8
AD - U.O. di Pneumologia e Fisiopatologia Respiratoria, Istituto Nazionale
per lo Studio e la Cura dei Tumor, Milano, Italy.
The aim of the present investigation was to evaluate lung function and
the time course of serum concentration of selected cytokines known to be
involved in pulmonary fibrosis, in 39 patients with stages IIB, III and
IV Hodgkin's disease submitted to intermediate-high dose chemotherapy,
(epirubicin, vincristine, cyclophosphamide, etoposide, prednisone)
followed by radiotherapy. Lung function tests were performed before, at
the end of treatment and after a follow-up of more than 12 months from
the end of the combined therapy. Tumor necrosis factor alpha,
fibronectin and Interleukins 4, 6 and 8 were determined on serum samples
collected at the same time intervals. In the patients, spirometric
parameters apparently improved whereas diffusing capacity for CO (DLCO)
decreased, TNF-alpha concentrations constantly decreased, fibronectin
and IL-8 showed a tendency to increase, but Interleukins 4 and 6 did not
show significant modifications. No significant correlations were
observed between the changes of lung function tests and serum cytokine
concentrations, probably because cytokine serum levels were not able to
reflect events occurring in the alveolar phase.
UI - 12188384
AU - Mitarnun W; Pradutkanchana J; Takao S; Saechan V; Suwiwat S; Ishida T
TI -
Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin,
Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a
serologic and molecular analysis.
SO - J Med Assoc Thai 2002 May;85(5):552-9
AD - Department of Pathology, Faculty of Medicine, Prince of Songkla
University, Thailand.
Parallel studies of (a) patients with Epstein-Barr virus
(EBV)-associated peripheral T-cell proliferative disease/lymphomas and
(b) a group of patients with a prolonged fever from other causes were
conducted at Songklanagarind University Hospital from 1997 through 2000.
(Reports on EBV-associated peripheral T-cell and NK-cell proliferative
disease/lymphomas have been published elsewhere) In this study, the
authors identified 58 patients; 14 were non-Hodgkin's lymphoma of B-cell
origin (NHL-B), 8 were Hodgkin's disease, 6 were acute leukemia, 9 were
systemic lupus erythematosus (SLE), and 21 were patients with other
diseases. Serologic tests for the EBV infection, the study of EBV genome
in circulating non-T-cells (CD3-cells) and T-cells (CD3+ cells), and the
EBV-RNA study in the tumor cells were performed. EBV internal repeat-1
region (IR-1) in peripheral blood CD3+ cells was detected in 10 of 14
patients (71.5%) with NHL-B, 3 of 8 patients (37.5%) with Hodgkin's
disease, 1 of 6 patients (16.7%) with acute leukemia, 4 of 9 patients
(44.5%) with SLE, and was not detected in any of the 21 patients with
other diseases. Anti-viral capsid antigen-IgG was significantly elevated
in hematologic malignancy patients with EBV IR-1 genome in the
peripheral blood CD3+ cells when compared to hematologic malignancy
patients with a negative result, whereas there was no significant
difference in anti-EBV nuclear antigen among these two groups. EBV-RNA
expression in tumor cells by in situ hybridization was detected in 4 of
13 patients (31%) with NHL-B (all showed EBV IR-1 genome in peripheral
blood CD3+ cells), and 3 of 5 patients (60%) with Hodgkin's disease
(only two showed EBV IR-1 genome in peripheral blood CD3+ cells). These
data support the theory that chronic EBV infection is often found in
association with cases of NHL-B, Hodgkin's disease, acute leukemia, and
SLE.
UI - 12100217
AU - de Vries HJ; Koopmans AK; Starink TM; Mekkes JR
TI -
Ofuji papuloerythroderma associated with Hodgkin's lymphoma.
SO - Br J Dermatol 2002 Jul;147(1):186-7
UI - 12145210
AU - Mathas S; Hinz M; Anagnostopoulos I; Krappmann D; Lietz A; Jundt F;
TI -
Bommert K; Mechta-Grigoriou F; Stein H; Dorken B; Scheidereit C
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma
cells, stimulate proliferation and synergize with NF-kappa B.
SO - EMBO J 2002 Aug 1;21(15):4104-13
AD - Max-Delbruck-Center for Molecular Medicine and Universitatsklinikum
Charite, Robert-Rossle-Klinik, Humboldt University, Lindenberger Weg 80,
D-13125 Berlin.
AP-1 family transcription factors have been implicated in the control of
proliferation, apoptosis and malignant transformation. However, their
role in oncogenesis is unclear and no recurrent alterations of AP-1
activities have been described in human cancers. Here, we show that
constitutively activated AP-1 with robust c-Jun and JunB overexpression
is found in all tumor cells of patients with classical Hodgkin's
disease. A similar AP-1 activation is present in anaplastic large cell
lymphoma (ALCL), but is absent in other lymphoma types. Whereas c-Jun is
up-regulated by an autoregulatory process, JunB is under control of
NF-kappa B. Activated AP-1 supports proliferation of Hodgkin cells,
while it suppresses apoptosis of ALCL cells. Furthermore, AP-1
cooperates with NF-kappa B and stimulates expression of the cell-cycle
regulator cyclin D2, proto-oncogene c-met and the lymphocyte homing
receptor CCR7, which are all strongly expressed in primary HRS cells.
Together, these data suggest an important role of AP-1 in lymphoma
pathogenesis.
UI - 11697486
AU - Lee IS; Shin YK; Chung DH; Park SH
TI -
LMP1-induced downregulation of CD99 molecules in Hodgkin and
Reed-Sternberg cells.
SO - Leuk Lymphoma 2001 Aug;42(4):587-94
AD - Department of Pathology, Seoul National University College of Medicine,
Korea.
Hodgkin's and Reed-Sternberg (H-RS) cells are morphological hallmarks of
Hodgkin's disease (HD). So far, several characteristics frequently seen
in H-RS cells from different origins have been described, such as the
high expression of Epstein-Barr virus latent membrane protein 1 (LMP1),
the elevation of NF-kappaB activity, and the aberrant expression of
molecules such as CD15, CD30, and CD99. Despite extensive studies on the
nature of H-RS cells, the molecular mechanism by which H-RS cells are
generated remained elusive. Recently, the forced down-regulation of CD99
was reported to induce typical H-RS phenotypes in vitro in a B cell
line. Furthermore, it was revealed that LMP1 markedly reduces the CD99
expression at the transcriptional level. Since the presence of LMP1 is
known to be associated with the H-RS cell formation, the data provide a
possibility of linkage between LMP1 and HD via CD99, thus suggesting
that, at least in part, the loss of CD99 may play a critical role in the
pathogenic sequence to the formation of H-RS cells in HD. In this
review, the role of CD99 in the generation of H-RS cells and its
molecular mechanism will be suggested.
UI - 11697494
AU - Guermazi A
TI -
Is it wise to eliminate lymphography from the staging of Hodgkin's
disease?
SO - Leuk Lymphoma 2001 Aug;42(4):655-60
AD - Department of Radiology Saint-Louis University Hospital, Paris, France.
guermazi@chu-stlouis.fr
We believe that lymphography and CT are complementary rather than
mutually exclusive techniques for the diagnosis and staging of HD.
Unfortunately, it seems that many radiologists and clinicians disregard
the ability of lymphography to provide qualitative information on lymph
node architecture, which is not available by CT. The use of lymphography
is declining in several teaching centers throughout the world. This
makes it difficult for young radiologists to acquire the skills needed
to perform and interpret lymphographies successfully. In turn,
radiologists who have little experience with lymphography are less
likely to use the technique. Because most of the treatment-related
morbidity in HD is dose-related, and because lymphography helps to avoid
over- and undertreatment, we believe that high-quality lymphography
continues to have a significant role in the staging of selected HD
patients. Moreover. lymphography may reduce both the cost of management
and the morbidity rate in many HD patients. One solution would be to
continue to use lymphography in a small number of institutions
specialized in the management of HD.
UI - 11697495
AU - Provencio M; Espana P; Salas C; Sanchez A; Bonilla F
TI -
Hodgkin's disease: unsuspected minimal activity in patients that die
from causes other than tumoral progression.
SO - Leuk Lymphoma 2001 Aug;42(4):661-4
AD - Department of Oncology, Hospital Universitario Clinica Puerta de Hierro,
Madrid, Spain.
Hodgkin's disease (HD) is a curable disease. However, there are still
many questions that remain unanswered in this illness, such as the
appearance of unsuspected microscopic active illness a long time after
the conclusion of treatment, We do not know of any recent publications
that have microscopically studied the presence of unsuspected HD
activity in patients who died from causes other than tumoral
progression. This aspect was analysed in our series of patients with HD.
We studied 486 patients with a median follow-up of 8 years. Autopsy was
performed in 40 of 144 non-surviving patients. Active HD was found in
60% (24/40) of the patients at autopsy. Of these, 10 patients (25%,
10/40) with active HD died from causes other than tumoral progression.
Six patients had minimal clinically unsuspected isolated tumor foci. In
spite of technical advances and the introduction of modern and more
aggressive chemotherapy, the discovery of minimal unsuspected residual
HD continues in an considerable percentage of patients who die from
causes other than tumoral progression.
UI - 1498073
AU - Pavlovsky S; Santarelli MT; Muriel FS; Fernandez I; Garcia I; Schwartz
TI -
L; Montero C; Sanahuja FL; Magnasco H; Costa A; et al
Randomized trial of chemotherapy versus chemotherapy plus radiotherapy
for stage III-IV A & B Hodgkin's disease.
SO - Ann Oncol 1992 Jul;3(7):533-7
AD - Grupo Argentino de Tratamiento de Leucemia Aguda (GATLA), Buenos Aires.
A total of 151 patients with previously untreated Hodgkin's disease,
clinical stages III-IV A & B, were randomized to receive CVPP for 6
cycles, or CVPP plus RT 3000 cGy to previously involved areas between
the 3rd and 4th cycles. CVPP consists of cyclophosphamide 600
mg/m2/i.v., vinblastine 6 mg/m2/i.v. on day 1, procarbazine 100
mg/m2/p.o. and prednisone 40 mg/m2/p.o. on days 1 to 14. Both groups
displayed similar clinical characteristics at diagnosis. Sixty-six were
treated with CVPP + RT (52 St III and 14 St IV) and 85 with CVPP alone
(68 St III and 17 St IV). Complete remission was obtained in 57 (86%) of
66 patients who received CVPP plus RT, and in 62 (73%) of 85 patients
treated with CVPP. Five and sixteen patients, respectively, achieved
partial responses, while 2 in each group died during treatment. At 7
years, duration of complete remission and failure-free survival were:
51% and 45% for those treated with CVPP plus RT, and 23% and 21% with
CVPP alone (p = 0.0150 and P = 0.0016, respectively). Overall survival
at 7 years was 71% and 58%, respectively (p = 0.1488). A dose analysis
performed in 84 pts showed that 91% and 88% received full protocol doses
of CPM and PCZ, respectively, in the CVPP + RT group, and 95% and 94%
for CVPP. The WBC nadir was 3.5 and 3.7 x mm3, respectively. Of 25 pts
on CVPP + RT who relapsed, 9 are now disease-free, 5 are alive with
disease and 11 have died, and with CVPP, of 37 relapsing pts, 18 are
disease-free, 5 are alive with disease and 14 are dead.(ABSTRACT
TRUNCATED AT 250 WORDS)
UI - 9572494
AU - Wood KM; Roff M; Hay RT
TI -
Defective IkappaBalpha in Hodgkin cell lines with constitutively active
NF-kappaB.
SO - Oncogene 1998 Apr 23;16(16):2131-9
AD - Department of Pathology, Royal Victoria Infirmary, Newcastle upon Tyne,
England.
The molecular mechanisms underlying Hodgkin's disease remain obscure,
but it has been recognized that the neoplastic cells display high levels
of constitutively active nuclear NF-kappaB. Here we demonstrate that
although nuclear NF-kappaB is transcriptionally active, the Hodgkin
cells fail to activate NF-kappaB dependent transcription in response to
CD40 ligand. In three Hodgkin cell lines examined each had abnormalities
in expression of IkappaBalpha which could account for the deregulated
NF-kappaB. Although all three cell lines had greater than normal levels
of IkappaBalpha mRNA no IkappaBalpha protein could be detected in the
KM-H2 cells, while the L428 cell line contains a C-terminally truncated
IkappaBalpha species that fails to associate with NF-kappaB. The HDLM-2
cell line contains a more slowly migrating form of IkappaBalpha that can
associate with NF-kappaB, but increasing the level of this protein
within the cell fails to inhibit nuclear NF-kappaB. Addition of
recombinant IkappaBalpha to nuclear extracts from all three cell lines
resulted in complete inhibition of NF-kappaB DNA binding activity and
introduction of a plasmid expressing IkappaBalpha into the cells
inhibited the transcriptional activity of an NF-kappaB dependent
reporter plasmid. Thus the constitutive expression of NF-kappaB in
Hodgkin cells is a direct consequence of the abnormal expression of
IkappaBalpha rather than changes in NF-kappaB that render it refractory
to inhibition by IkappaB proteins. These changes could, at least in
part, account for the characteristic activated phenotype of Hodgkin
cells and their pattern of cytokine secretion, which determine the
pathological appearance and clinical manifestations of Hodgkin's
disease.
UI - 10340377
AU - Cabannes E; Khan G; Aillet F; Jarrett RF; Hay RT
TI -
Mutations in the IkBa gene in Hodgkin's disease suggest a tumour
suppressor role for IkappaBalpha.
SO - Oncogene 1999 May 20;18(20):3063-70
AD - School of Biomedical Science, University of St Andrews, Fife, UK.
The NF-kappaB/Rel family of transcription factors regulates a wide
variety of genes whose products play a fundamental role in inflammatory
and immune responses. The implication of NF-kappaB/Rel proteins and
their IkappaB regulatory subunits in the control of cellular growth and
oncogenesis, was suggested by the induction of fatal lymphomas in birds
by the v-rel oncoprotein, and the rearrangement and amplification of
several genes encoding the NF-kappaB/Rel/IkappaB signal transduction
factors in human malignancies, primarily of lymphoid origin. Hodgkin's
disease (HD) is a lymphoma characterized by a low frequency of malignant
Hodgkin and Reed-Sternberg (H/RS) cells in a reactive background of
non-neoplastic cells. The peculiar activated phenotype of Hodgkin and
Reed-Sternberg cells and their pattern of cytokine secretion are
believed to be a consequence of constitutive activation of the NF-kappaB
transcription factor. Here, we report the detection of mutations of the
IkBa gene, in two HD-derived cell lines and in two out of eight biopsy
samples from patients with relapsed Hodgkin's disease. The presence of
defective IkappaBalpha is thus likely to explain the constitutive
activation of NF-kappaB in these cells and suggests that IkappaBalpha is
a tumour suppressor controlling the oncogenic activation of NF-kappaB in
Hodgkin and Reed-Sternberg cells.
UI - 10564680
AU - Pajonk F; Pajonk K; McBride WH
TI -
Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human
cancer cells.
SO - J Natl Cancer Inst 1999 Nov 17;91(22):1956-60
AD - Department of Radiation Oncology, Experimental Division, University of
California at Los Angeles School of Medicine 10833, USA.
fpajonk@u
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
